Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Tools & Techniques Cancer, Diagnostics & prognostics

The Rise of ctDNA, Part Two

What do we know about the early stages of lung cancer? Not much, because most cases are only diagnosed in late stages, once the symptoms have become unmistakable – and even relapses are often missed at first. Given that lung cancer is both the most common cancer worldwide and the leading cause of cancer death, it’s vital that we learn as much as we can about how the disease evolves – and what we may be able to do to detect and stop it early.

To that end, a group of researchers have performed circulating tumor DNA (ctDNA) profiling on the first 100 participants in the TRACERx (Tracking non-small cell lung Cancer Evolution through therapy) study, taking a tumor-specific, phylogenetic approach (1). What does that mean? The team were able to spot early predictors of ctDNA release, detect resistance to adjuvant chemotherapy, and identify patients likely to experience a relapse. But the method’s power doesn’t stop there – researchers were even able to keep track of the molecular profiles of recurrent and metastatic tumors, allowing them to observe the cancer’s evolution and potentially opening the door to future personalized treatments.

The science isn’t quite ready for prime time yet. Its sensitivity is constrained by tumor volume; the smallest tumors visible by standard imaging correlate with plasma ctDNA levels at the very extreme of current detection limits – and the cost of targeted ctDNA profiling is still a significant burden. But there’s a clear need to improve current treatments, whose success rates are low and toxicities high. If ctDNA profiling can provide insights into which patients are most likely to relapse and which cancers are most susceptible to chemotherapy, then as technologies improve and costs drop, we may one day be able to offer every lung cancer patient the treatment most likely to yield a cure.

Receive content, products, events as well as relevant industry updates from The Translational Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. C Abbosh et al., “Phylogenetic ctDNA analysis depicts early stage lung cancer evolution”, Nature, [Epub ahead of print] (2017). PMID: 28445469.
About the Author
Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts